← All market reports

HIV / ARV Market Research Reports 2026

HIV / ARV growth opportunities become clearer when country-level access constraints and treatment workflow realities are reviewed together.

Sub-Saharan Africa carries 67% of the global HIV burden (25.6M of 39M PLHIV globally, UNAIDS 2023). South Africa (7.5M PLHIV), Nigeria (1.9M), and Tanzania (1.7M) are the three largest HIV-affected populations and anchor PEPFAR- and Global Fund–financed treatment programmes where tenofovir/lamivudine/dolutegravir (TLD) is the WHO-preferred first-line backbone. Integrase strand transfer inhibitors—including dolutegravir, bictegravir, and cabotegravir—have displaced efavirenz-based regimens in high-burden public sectors because of superior viral suppression, tolerability, and resistance profiles. GCC countries have <0.1% adult HIV prevalence — negligible commercial impact for originator ARV franchises relative to metabolic, oncology, or immunology portfolios. Commercial strategy therefore bifurcates sharply: sub-scale confidential treatment pathways in Saudi Arabia, UAE, and Qatar versus high-volume, donor-procured corridors in Nigeria, Kenya, and South Africa where Aspen Pharmacare, Cipla, and Indian generic manufacturers dominate supply at price points incompatible with premium branded positioning.

Explore all market reports or compare market-level rollout constraints in the GCC country report hub. Current coverage includes .